CC
BBIO icon

Centiva Capital’s BridgeBio Pharma BBIO Stock Holding History

Centiva Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,680
Closed -$591K – 1129
2025
Q2 		$591K Buy
+13,680
New +$498K 0.01% 890
2023
Q2 		– Sell
-11,900
Closed -$197K – 1637
2023
Q1 		$197K Buy
+11,900
New +$139K ﹤0.01% 1246
2021
Q2 		– Sell
-16,081
Closed -$991K – 1382
2021
Q1 		$991K Buy
16,081
+11,369
+241% +$744K 0.04% 358
2020
Q4 		$335K Buy
+4,712
New +$227K 0.01% 615
2020
Q1 		– Sell
-17,875
Closed -$627K – 624
2019
Q4 		$627K Buy
+17,875
New +$496K 0.03% 378

Other funds holding BBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's BBIO Position: Q3 2025 in Review

Centiva Capital sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 13,680 shares — an estimated $591K sold.

Centiva Capital first reported a position in BBIO in Q4 2019 and held it in 5 quarters. The position peaked at $991K in Q1 2021. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Centiva Capital reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 13,680 BridgeBio Pharma shares in Q3 2025, an estimated $591K.
  • Centiva Capital first reported a position in BridgeBio Pharma in Q4 2019 and held it in 5 quarters.
  • Centiva Capital's BridgeBio Pharma position peaked at $991K in Q1 2021.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.